T-cell receptor gene transfer for treatment of leukemia

References

• Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med 2003; 54: 491–512
   PubMed Web of Science ®Google Scholar
• Collins RH, Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–44
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–5
   PubMed Web of Science ®Google Scholar
• Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100–6
   PubMed Web of Science ®Google Scholar
• Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999; 5: 839–42
   PubMed Web of Science ®Google Scholar
• Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410–14
   PubMed Web of Science ®Google Scholar
• Marijt EA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742–7
   PubMed Web of Science ®Google Scholar
• de Bueger M, Bakker A, van Rood JJ, et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788–94
   PubMed Web of Science ®Google Scholar
• Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med 2003; 197: 1489–500
   PubMed Web of Science ®Google Scholar
• de Rijke B, Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005; 115: 3506–16
   PubMed Web of Science ®Google Scholar
• Slager EH, Honders MW, van der Meijden ED, et al. Identification of the angiogenic endothelial cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006; 107: 4954–60
   PubMed Web of Science ®Google Scholar
• Dolstra H, Fredrix H, Maas F, et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301–8
   PubMed Web of Science ®Google Scholar
• Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 2006; 107: 3779–86
   PubMed Web of Science ®Google Scholar
• Kawase T, Akatsuka Y, Torikai H, et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 2007; 110: 1055–63
   PubMed Web of Science ®Google Scholar
• Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198–203
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405–12
   PubMed Web of Science ®Google Scholar
• Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450–7
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038–44
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551–5
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004; 101(Suppl 2)14639–45
   PubMed Web of Science ®Google Scholar
• Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201–8
   PubMed Web of Science ®Google Scholar
• Marijt E, Wafelman A, van der Hoorn M, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica 2007; 92: 72–80
   PubMed Web of Science ®Google Scholar
• Dembic Z, Haas W, Weiss S, et al. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 1986; 320: 232–8
   PubMed Web of Science ®Google Scholar
• Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163: 507–13
   PubMed Web of Science ®Google Scholar
• Fujio K, Misaki Y, Setoguchi K, et al. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol 2000; 165: 528–32
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, de Paus RA, Lurvink EG, et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci USA 2001; 98: 6806–11
   PubMed Web of Science ®Google Scholar
• Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein–Barr virus-encoded peptide. Clin Immunol 2001; 98: 220–8
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of anti-leukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2 specific T cell receptor complexes expressing a conserved alpha joining region. Blood 2003; 102: 3530–40
   PubMed Web of Science ®Google Scholar
• Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962–70
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004; 199: 885–94
   PubMed Web of Science ®Google Scholar
• Rubinstein MP, Kadima AN, Salem ML, et al. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol 2003; 170: 1209–17
   PubMed Web of Science ®Google Scholar
• Kessels HW, Wolkers MC, van den Boom MD, et al. Immunotherapy through TCR gene transfer. Nat Immunol 2001; 2: 957–61
   PubMed Web of Science ®Google Scholar
• Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005; 106: 3062–7
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126–9
   PubMed Web of Science ®Google Scholar
• Labrecque N, Whitfield LS, Obst R, et al. How much TCR does a T cell need?. Immunity 2001; 15: 71–82
   PubMed Web of Science ®Google Scholar
• Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA 1996; 93: 13114–18
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Zheng Z, Bray R, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol 2005; 175: 5799–808
   PubMed Web of Science ®Google Scholar
• Kuball J, Schmitz FW, Voss RH, et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005; 22: 117–29
   PubMed Web of Science ®Google Scholar
• Holler PD, Holman PO, Shusta EV, et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci USA 2000; 97: 5387–92
   PubMed Web of Science ®Google Scholar
• Kessels HW, van den Boom MD, Spits H, et al. Changing T cell specificity by retroviral T cell receptor display. Proc Natl Acad Sci USA 2000; 97: 14578–83
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR–CD3 complex. Blood 2007; 109: 235–43
   PubMed Web of Science ®Google Scholar
• Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119: 135–45
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–6
   PubMed Web of Science ®Google Scholar
• Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303: 333
   PubMed Web of Science ®Google Scholar
• Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003; 9: 367–9
   PubMed Web of Science ®Google Scholar
• Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Curr Opin Immunol 2001; 13: 141–6
   PubMed Web of Science ®Google Scholar
• Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–24
   PubMed Web of Science ®Google Scholar
• Berger C, Blau CA, Huang ML, et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 2004; 103: 1261–9
   PubMed Web of Science ®Google Scholar
• Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247–54
   PubMed Web of Science ®Google Scholar
• Sommermeyer D, Neudorfer J, Weinhold M, et al. Designer T cells by T cell receptor replacement. Eur J Immunol 2006; 36: 3052–9
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Li YF, El Gamil M, et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898–903
   PubMed Web of Science ®Google Scholar
• Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331–8
   PubMed Web of Science ®Google Scholar
• van der Veken LT, Hagedoorn RS, van Loenen MM, et al. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res 2006; 66: 3331–7
   PubMed Web of Science ®Google Scholar
• Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA 2005; 102: 4518–23
   PubMed Web of Science ®Google Scholar
• van Lent AU, Nagasawa M, van Loenen MM, et al. Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol 2007; 179: 4959–68
   PubMed Web of Science ®Google Scholar
• Zhao Y, Parkhurst MR, Zheng Z, et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res 2007; 67: 2425–9
   PubMed Web of Science ®Google Scholar